Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-risk Osteosarcoma.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2014
At a glance
- Drugs Mifamurtide (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 31 Aug 2018 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2013 Planned end date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.